Verrica Pharmaceuticals (STU:1NE0) ROCE %: -144.09% (As of Mar. 2026)

What is Verrica Pharmaceuticals ROCE %?

Verrica Pharmaceuticals STU:1NE0 -0.56% 45 ROCE % is -144.09% as of Mar. 2026. GuruFocus rates STU:1NE0 with a GF Score™ of 45/100 and a GF Value™ of €12.59 (Possible Value Trap). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Verrica Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -144.09%.

Verrica Pharmaceuticals (STU:1NE0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Verrica Pharmaceuticals ROCE % Related Terms

Verrica Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Verrica Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verrica Pharmaceuticals ROCE % Chart

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-92.89

-60.97

-117.76

-154.18

-34.51

Verrica Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-155.77	79.39	66.06	-126.79	-144.09

45GF Score

Verrica Pharmaceuticals Inc STU:1NE0

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Verrica Pharmaceuticals ROCE % Calculation

Verrica Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-8.663	/	( ( (51.698 - 27.706)	+	(40.25 - 14.037) )	/ 2 )
	=	-8.663	/	( (23.992	+	26.213)	/ 2 )
	=	-8.663	/	25.1025
	=	-34.51 %

Verrica Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-32.948	/	( ( (40.25 - 14.037)	+	(33.55 - 14.029) )	/ 2 )
	=	-32.948	/	( ( 26.213	+	19.521 )	/ 2 )
	=	-32.948	/	22.867
	=	-144.09 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -144.09% mean?

Verrica Pharmaceuticals (STU:1NE0) has a ROCE % of -144.09% as of Mar. 2026.

Is Verrica Pharmaceuticals' ROCE % too high?

Verrica Pharmaceuticals' current ROCE % is -144.09%. Overall, Verrica Pharmaceuticals has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Verrica Pharmaceuticals' ROCE % compare to ENGN and PEPG?

Verrica Pharmaceuticals' ROCE % of -144.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Verrica Pharmaceuticals's current ROCE % is -144.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Verrica Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Verrica Pharmaceuticals (STU:1NE0) is currently considered Possible Value Trap. The stock's GF Value™ is €12.59, compared to a current price of €5.31 — trading 57.8% below its estimated fair value. The current ROCE % is -144.09%. Verrica Pharmaceuticals' overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Verrica Pharmaceuticals (STU:1NE0), the current ROCE % is -144.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Verrica Pharmaceuticals (STU:1NE0) Overvalued in 2026?

Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued. The current stock price of €5.31 is trading 57.8% below its estimated GF Value™ of €12.59. GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.

Key valuation signals for STU:1NE0:

ROCE %: -144.09%
GF Value™: €12.59 vs. price of €5.31 (57.8% below fair value)
GF Score™: 45/100 with 2 warning signs

No single metric tells the full story. See the STU:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Verrica Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ENGN PEPG ONCY NTHI GUTS PLYX ALDX CUE LIXT ALPS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges VRCA:USA 1NE0:Germany

Address 44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website https://www.verrica.com

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

45GF Score

Get the complete analysis for STU:1NE0

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.31

Price

€12.59

GF Value

View STU:1NE0 Analysis

See ROCE % data for all stocks →